|
Corporate Name |
Chordia Therapeutics Inc. |
|
Establishment |
12th October, 2017 |
|
Head Office |
26-1, Muraoka-Higashi 2-chome, Fujisawa,Kanagawa, 251-0012 Japan |
|
Tokyo Office |
3-11-5, Nihonbashi-honcho, Chuo-ku, Tokyo 103-0023 Japan |
|
Representative |
Hiroshi Miyake, Ph.D. CEO |
Head Office
Tokyo Office
|
October 2017 |
Launch of Chordia Therapeutics |
|
November 2017 |
Raises around $11 million in Series A Financing |
|
November 2018 |
Initiate Phase 1 Study for rogocekib |
|
March 2019 |
Raises around $27 million in Series B Financing |
|
November 2020 |
Entered into a license agreement with Takeda for exclusive worldwide rights to 4 programs |
|
December 2020 |
Notice of license agreement with Ono Pharmaceutical （Return of rights on April 28, 2025） |
|
May 2022 |
Raises around $31 million in Series C Financing |
|
February 2023 |
Initiate Phase 1/2 Clinical Study in US |
|
June 2024 |
Listed on the Tokyo Stock Exchange Growth Market |
